Pfizer stock edges higher to $25.66 as Pfizer presents blood disorder data at EHA2026

Traders Union
All News
Companies
Pfizer up 0.16% today at $25.66

Highlights

Pfizer remains under persistent selling pressure, trading below major moving averages and failing to break immediate resistance near $25.97.
Momentum and oscillator signals are predominantly bearish, with weak trend indicators and steady downward price action throughout the week.
Next week's trading is likely range-bound between $25.10 and $25.90, with a higher probability of further downside unless $25.97 resistance is reclaimed.

Seller pressure entrenched as key averages cap upside

Pfizer ($25.66) remains below its MA-20 ($25.77), MA-50 ($26.52), and MA-200 ($25.85), reflecting persistent seller pressure in the short, medium, and long term. The Ichimoku Kijun is at $25.97, acting as immediate resistance; near-term support is seen at MA-20 ($25.77) and MA-200 ($25.85), with key support at MA-50 ($26.52); immediate resistance lies at the Kijun ($25.97) and then MA-50 ($26.52) as key.

Bearish momentum prevails amid weak trend and volatile declines

Momentum signals on D1 remain negative, with MACD firmly in strong sell territory and ADX at a weak 8.88, indicating a trendless or consolidating market. D1 RSI is at 44.64 (sell) and the Stoch RSI is neutral, while CCI hovers near neutral but with some sell signals intraday. BBP is modestly positive at 0.10, showing mixed buyer influence, but most oscillator signals point to ongoing seller dominance. Over the past week, Pfizer has fallen $0.35 (1.35%) from a prev_week_close of $26.01, with the current price positioned in the lower part of the weekly range after earlier lows at $25.29. Weekly volatility stands at 3.68%. The week’s tone is one of steady decline from the high, and this weak performance aligns with prevailing bearish momentum.

Downside risk favored as bullish triggers face low probability

For the next week, the expected trading range for Pfizer is $25.10 to $25.90, keeping price action above the 52-week low ($23.11) and below the 52-week high ($28.74). Based on W1 indicators showing only ADX with a "Buy" and all other signals bearish or neutral, there is a very low probability (less than 20%) of a meaningful price increase, making further downside more likely. Baseline scenario suggests Pfizer remains sideways within this corridor. In a bullish scenario, a sustained push above immediate resistance at $25.97 could open room to test $26.50. Bearish momentum may intensify if $25.77 fails, potentially testing toward $25.10 or the lower end of this week’s range.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Pfizer was trading within a rangebound pattern as mixed technical signals kept the outlook neutral. With new developments now under consideration, investors should closely watch for a sustained directional break that could indicate the stock’s next significant move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.